These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15037657)

  • 21. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.
    Deacu E; Mori Y; Sato F; Yin J; Olaru A; Sterian A; Xu Y; Wang S; Schulmann K; Berki A; Kan T; Abraham JM; Meltzer SJ
    Cancer Res; 2004 Nov; 64(21):7690-6. PubMed ID: 15520171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transforming growth factor-beta 1 mediated alterations in ribonucleotide reductase gene expression in BALB/c 3T3 fibroblasts.
    Hurta RA; Greenberg AH; Wright JA
    J Cell Physiol; 1992 Sep; 152(3):529-35. PubMed ID: 1506411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signaling cross-talk between IGF-binding protein-3 and transforming growth factor-(beta) in mesenchymal chondroprogenitor cell growth.
    O'Rear L; Longobardi L; Torello M; Law BK; Moses HL; Chiarelli F; Spagnoli A
    J Mol Endocrinol; 2005 Jun; 34(3):723-37. PubMed ID: 15956343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
    Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB
    Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Requirement of TGF-beta receptor-dependent activation of c-Jun N-terminal kinases (JNKs)/stress-activated protein kinases (Sapks) for TGF-beta up-regulation of the urokinase-type plasminogen activator receptor.
    Yue J; Sun B; Liu G; Mulder KM
    J Cell Physiol; 2004 May; 199(2):284-92. PubMed ID: 15040011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble transforming growth factor beta type II receptor attenuates TGF-beta1 activity in human colorectal cancer LoVo cells.
    Zhou R; Xiong B; Song H; Liu S; Wang X
    Oncol Rep; 2008 Dec; 20(6):1449-56. PubMed ID: 19020727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
    Yagyu T; Kobayashi H; Wakahara K; Matsuzaki H; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
    FEBS Lett; 2004 Oct; 576(3):408-16. PubMed ID: 15498571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of transforming growth factor beta on human neuroendocrine tumor BON cell proliferation and differentiation is mediated through somatostatin signaling.
    Leu FP; Nandi M; Niu C
    Mol Cancer Res; 2008 Jun; 6(6):1029-42. PubMed ID: 18567806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upstream stimulatory factor regulates E box-dependent PAI-1 transcription in human epidermal keratinocytes.
    Allen RR; Qi L; Higgins PJ
    J Cell Physiol; 2005 Apr; 203(1):156-65. PubMed ID: 15372465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
    Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
    Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cathepsin G-mediated activation of pro-matrix metalloproteinase 9 at the tumor-bone interface promotes transforming growth factor-beta signaling and bone destruction.
    Wilson TJ; Nannuru KC; Singh RK
    Mol Cancer Res; 2009 Aug; 7(8):1224-33. PubMed ID: 19671689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas.
    Iolascon A; Giordani L; Borriello A; Carbone R; Izzo A; Tonini GP; Gambini C; Della Ragione F
    Br J Cancer; 2000 Mar; 82(6):1171-6. PubMed ID: 10735501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Control and expression of cystatin C by mouse decidual cultures.
    Afonso S; Tovar C; Romagnano L; Babiarz B
    Mol Reprod Dev; 2002 Feb; 61(2):155-63. PubMed ID: 11803549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type I transforming growth factor-beta receptors on neutrophils mediate chemotaxis to transforming growth factor-beta.
    Brandes ME; Mai UE; Ohura K; Wahl SM
    J Immunol; 1991 Sep; 147(5):1600-6. PubMed ID: 1652608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model.
    Dorigo O; Shawler DL; Royston I; Sobol RE; Berek JS; Fakhrai H
    Gynecol Oncol; 1998 Nov; 71(2):204-10. PubMed ID: 9826461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An antibody present in normal human serum inhibits the binding of cytokines to their receptors in an in vitro system.
    Mosedale DE; Grainger DJ
    Biochem J; 1999 Oct; 343 Pt 1(Pt 1):125-33. PubMed ID: 10493920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of transforming growth factor beta in cancer.
    Pasche B
    J Cell Physiol; 2001 Feb; 186(2):153-68. PubMed ID: 11169452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HOXD3 enhances motility and invasiveness through the TGF-beta-dependent and -independent pathways in A549 cells.
    Miyazaki YJ; Hamada J; Tada M; Furuuchi K; Takahashi Y; Kondo S; Katoh H; Moriuchi T
    Oncogene; 2002 Jan; 21(5):798-808. PubMed ID: 11850808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cloning and characterization of a transforming growth factor beta 1-induced anti-apoptotic adhesion protein TIF2.
    Carey GB; Chang NS
    Biochem Biophys Res Commun; 1998 Aug; 249(1):283-6. PubMed ID: 9705873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical efficacy of cystatin C to target the oncogenic activity of transforming growth factor Beta in breast cancer.
    Tian M; Schiemann WP
    Transl Oncol; 2009 Aug; 2(3):174-83. PubMed ID: 19701502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.